Joey L. Methot

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

17h-index1.8kcitations49works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Histone Deacetylase Inhibitors Research(11), Protein Degradation and Inhibitors(10), Peptidase Inhibition and Analysis(8), PI3K/AKT/mTOR signaling in cancer(7), Chronic Lymphocytic Leukemia Research(7)

Publications49 total

WRN structural flexibility showcased through fragment-based lead discovery of inhibitors
Nature Communications·2026Open Access
WRN structural flexibility showcased through fragment-based lead discovery of inhibitors
Figshare·2026Open Access
WRN structural flexibility showcased through fragment-based lead discovery of inhibitors
Figshare·2026Open Access
WRN helicase structural flexibility showcased through fragment-based lead discovery of inhibitors
Structural Dynamics·2025Open Access
High-throughput evaluation of novel WRN inhibitors
SLAS DISCOVERY·2025Open Access
The Discovery of Bridged Benzoazepine Amides as Selective Allosteric Modulators of RIPK1
ACS Medicinal Chemistry Letters·2025· 1 cited
High-Throughput Covalent Modifier Screening with Acoustic Ejection Mass Spectrometry
Journal of the American Chemical Society·2024· 16 cited
Abstract 2097: ABT co-dose accelerated target validation with a fit-for-purpose HPK1 inhibitor tool
Cancer Research·2024
Data from Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities
2023Open Access
Supplementary Methods, Figures 1 - 3, Tables 1 - 3 from Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities
2023Open Access
Supplementary Methods, Figures 1 - 3, Tables 1 - 3 from Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities
2023Open Access
Data from Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities
2023Open Access
CCDC 2206667: Experimental Crystal Structure Determination
The Cambridge Structural Database·2022Open Access
Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1 <i>H</i> -Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s Disease
Journal of Medicinal Chemistry·2022· 19 citedOpen Access
Discovery of a new series of PI3K-δ inhibitors from Virtual Screening
Bioorganic & Medicinal Chemistry Letters·2021· 4 citedOpen Access
Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3Kδ Immunomodulators
Journal of Medicinal Chemistry·2021· 7 citedOpen Access
Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds
ACS Medicinal Chemistry Letters·2021· 47 citedOpen Access
Identification of Potent Reverse Indazole Inhibitors for HPK1
ACS Medicinal Chemistry Letters·2021· 35 citedOpen Access
Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitors
RSC Medicinal Chemistry·2021· 14 citedOpen Access
BindingDB Entry 50007751: Structure Overhaul Affords a Potent Purine PI3Kδ Inhibitor with Improved Tolerability.
PubMed·2021· 7 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Charles A. Lesburg(14), Sanjiv Shah(14), Xavier Fradera(13), Bethany Hughes(11), Astrid M. Kral(11), Nicole Ozerova(11), Solomon D. Kattar(10), Jason D. Katz(10), Candia M. Kenific(9), Alexander A. Szewczak(9), J. Paul Secrist(9), Armetta Hill(9), R.L. Palte(9), Peter Goldenblatt(9), Richard E. Middleton(8), Thomas A. Miller(8), Robbie L. McLeod(8), My Sam Mansueto(8), Michael D. Altman(8), Jonathan C. Cruz(7)